KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients

This study aims to investigate the efficacy of bevacizumab-combined chemotherapy (BCC) in Chinese stage IV colorectal cancer (CRC), and analyze the relationship between clinicopathological features with survival. Patients with stage IV CRC treated with BCC were analyzed retrospectively. 217 metastat...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Sci Rep
Hlavní autoři: Sun, De-cong, Shi, Yan, Wang, Yan-rong, Lv, Yao, Yan, Huan, Mao, Hui, Wang, Zhi-kuan, Wu, Zhi-yong, Shi, Wei-wei, Dai, Guang-hai
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2017
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5662591/
https://ncbi.nlm.nih.gov/pubmed/29085005
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-14669-2
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky